_id
6919e4103c536f8df231806c
Ticker
AGL.LSE
Name
ANGLE plc
Exchange
LSE
Address
Surrey Research Park, Guildford, United Kingdom, GU2 7AF
Country
UK
Sector
Healthcare
Industry
Diagnostics & Research
Currency
GBX
Website
https://angleplc.com
Description
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. ANGLE plc was founded in 1994 and is based in Guildford, the United Kingdom.
Last Close
1.15
Volume
11468101
Current Price
1.1
Change
-1.3
Last Updated
2025-11-26T08:32:02.737Z
Image
-
Ipo Date
-
Market Cap
8444381
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
398000
Cost Of Revenue
165000
Gross Profit
233000
Operating Expenses
5071500
Operating Income
-9677000
Interest Expense
151000
Pretax Income
-9732000
Net Income
-4634000
Eps
-0.014367726596139939
Dividends Per Share
-
Shares Outstanding
322528409
Income Tax Expense
-464000
EBITDA
-4618000
Operating Margin
-2431.407035175879
Total Other Income Expense Net
-55000
Cash
5270000
Short Term Investments
-
Receivables
1681000
Inventories
1573000
Total Current Assets
9868000
Property Plant Equipment
5585000
Total Assets
18084000
Payables
2201000
Short Term Debt
1710000
Long Term Debt
-
Total Liabilities
6390000
Equity
11694000
Depreciation
425000
Change In Working Capital
145000
Cash From Operations
-4502000
Capital Expenditures
43500
Cash From Investing
-117000
Cash From Financing
-663000
Net Change In Cash
-5155000
PE
-
PB
30.338742081409272
ROE
-39.62715922695399
ROA
-25.624861756248617
FCF
-4545500
Fcf Percent
-11.420854271356784
Piotroski FScore
1
Health Score
23
Deep Value Investing Score
4
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
3.5
Quality Investing Score
2
Value Investing Score
2.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
398000
Quarters > 0 > income Statement > cost Of Revenue
165000
Quarters > 0 > income Statement > gross Profit
233000
Quarters > 0 > income Statement > operating Expenses
5071500
Quarters > 0 > income Statement > operating Income
-9677000
Quarters > 0 > income Statement > interest Expense
151000
Quarters > 0 > income Statement > pretax Income
-9732000
Quarters > 0 > income Statement > net Income
-4634000
Quarters > 0 > income Statement > eps
-0.014367726596139939
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
322528409
Quarters > 0 > income Statement > income Tax Expense
-464000
Quarters > 0 > income Statement > EBITDA
-4618000
Quarters > 0 > income Statement > operating Margin
-2431.407035175879
Quarters > 0 > income Statement > total Other Income Expense Net
-55000
Quarters > 0 > balance Sheet > cash
5270000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1681000
Quarters > 0 > balance Sheet > inventories
1573000
Quarters > 0 > balance Sheet > total Current Assets
9868000
Quarters > 0 > balance Sheet > property Plant Equipment
5585000
Quarters > 0 > balance Sheet > total Assets
18084000
Quarters > 0 > balance Sheet > payables
2201000
Quarters > 0 > balance Sheet > short Term Debt
1710000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
6390000
Quarters > 0 > balance Sheet > equity
11694000
Quarters > 0 > cash Flow > net Income
-4634000
Quarters > 0 > cash Flow > depreciation
425000
Quarters > 0 > cash Flow > change In Working Capital
145000
Quarters > 0 > cash Flow > cash From Operations
-4502000
Quarters > 0 > cash Flow > capital Expenditures
43500
Quarters > 0 > cash Flow > cash From Investing
-117000
Quarters > 0 > cash Flow > cash From Financing
-663000
Quarters > 0 > cash Flow > net Change In Cash
-5155000
Quarters > 0 > ratios > PE
-0.014367726596139939
Quarters > 0 > ratios > PB
30.338742081409272
Quarters > 0 > ratios > ROE
-39.62715922695399
Quarters > 0 > ratios > ROA
-25.624861756248617
Quarters > 0 > ratios > FCF
-4545500
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-11.420854271356784
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
398000
Quarters > 1 > income Statement > cost Of Revenue
165000
Quarters > 1 > income Statement > gross Profit
233000
Quarters > 1 > income Statement > operating Expenses
5071500
Quarters > 1 > income Statement > operating Income
-4838500
Quarters > 1 > income Statement > interest Expense
27500
Quarters > 1 > income Statement > pretax Income
-4866000
Quarters > 1 > income Statement > net Income
-4634000
Quarters > 1 > income Statement > eps
-0.014367726596139939
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
322528409
Quarters > 1 > income Statement > income Tax Expense
232000
Quarters > 1 > income Statement > EBITDA
-4618000
Quarters > 1 > income Statement > operating Margin
-1215.7035175879396
Quarters > 1 > income Statement > total Other Income Expense Net
-27500
Quarters > 1 > balance Sheet > cash
5270000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
1681000
Quarters > 1 > balance Sheet > inventories
1573000
Quarters > 1 > balance Sheet > total Current Assets
9868000
Quarters > 1 > balance Sheet > property Plant Equipment
5585000
Quarters > 1 > balance Sheet > total Assets
18084000
Quarters > 1 > balance Sheet > payables
2201000
Quarters > 1 > balance Sheet > short Term Debt
855000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
6390000
Quarters > 1 > balance Sheet > equity
11694000
Quarters > 1 > cash Flow > net Income
-4634000
Quarters > 1 > cash Flow > depreciation
425000
Quarters > 1 > cash Flow > change In Working Capital
145000
Quarters > 1 > cash Flow > cash From Operations
-2299000
Quarters > 1 > cash Flow > capital Expenditures
43500
Quarters > 1 > cash Flow > cash From Investing
-10500
Quarters > 1 > cash Flow > cash From Financing
-331500
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > ratios > PE
-0.014367726596139939
Quarters > 1 > ratios > PB
30.338742081409272
Quarters > 1 > ratios > ROE
-39.62715922695399
Quarters > 1 > ratios > ROA
-25.624861756248617
Quarters > 1 > ratios > FCF
-2342500
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-5.885678391959799
Quarters > 1 > health Score
23
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
914000
Quarters > 2 > income Statement > cost Of Revenue
330000
Quarters > 2 > income Statement > gross Profit
584000
Quarters > 2 > income Statement > operating Expenses
3980500
Quarters > 2 > income Statement > operating Income
-3396500
Quarters > 2 > income Statement > interest Expense
189000
Quarters > 2 > income Statement > pretax Income
-3386500
Quarters > 2 > income Statement > net Income
-3256000
Quarters > 2 > income Statement > eps
-0.010073754486069347
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
323216136
Quarters > 2 > income Statement > income Tax Expense
-130500
Quarters > 2 > income Statement > EBITDA
-3182000
Quarters > 2 > income Statement > operating Margin
-371.60831509846827
Quarters > 2 > income Statement > total Other Income Expense Net
10000
Quarters > 2 > balance Sheet > cash
10425000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1798000
Quarters > 2 > balance Sheet > inventories
1579000
Quarters > 2 > balance Sheet > total Current Assets
16408000
Quarters > 2 > balance Sheet > property Plant Equipment
6402000
Quarters > 2 > balance Sheet > total Assets
25458000
Quarters > 2 > balance Sheet > payables
695000
Quarters > 2 > balance Sheet > short Term Debt
1724000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
7017000
Quarters > 2 > balance Sheet > equity
18441000
Quarters > 2 > cash Flow > net Income
-3256000
Quarters > 2 > cash Flow > depreciation
443500
Quarters > 2 > cash Flow > change In Working Capital
-148500
Quarters > 2 > cash Flow > cash From Operations
-6448000
Quarters > 2 > cash Flow > capital Expenditures
141000
Quarters > 2 > cash Flow > cash From Investing
-311000
Quarters > 2 > cash Flow > cash From Financing
-704000
Quarters > 2 > cash Flow > net Change In Cash
-7457000
Quarters > 2 > ratios > PE
-0.010073754486069347
Quarters > 2 > ratios > PB
19.27974348462665
Quarters > 2 > ratios > ROE
-17.656309310774905
Quarters > 2 > ratios > ROA
-12.789692827401996
Quarters > 2 > ratios > FCF
-6589000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-7.208971553610503
Quarters > 2 > health Score
26
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
914000
Quarters > 3 > income Statement > cost Of Revenue
330000
Quarters > 3 > income Statement > gross Profit
584000
Quarters > 3 > income Statement > operating Expenses
3980500
Quarters > 3 > income Statement > operating Income
-3396500
Quarters > 3 > income Statement > interest Expense
188000
Quarters > 3 > income Statement > pretax Income
-3386500
Quarters > 3 > income Statement > net Income
-3256000
Quarters > 3 > income Statement > eps
-0.010073754486069347
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
323216136
Quarters > 3 > income Statement > income Tax Expense
-130500
Quarters > 3 > income Statement > EBITDA
-3182000
Quarters > 3 > income Statement > operating Margin
-371.60831509846827
Quarters > 3 > income Statement > total Other Income Expense Net
10000
Quarters > 3 > balance Sheet > cash
10425000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
2087000
Quarters > 3 > balance Sheet > inventories
1579000
Quarters > 3 > balance Sheet > total Current Assets
16408000
Quarters > 3 > balance Sheet > property Plant Equipment
6402000
Quarters > 3 > balance Sheet > total Assets
25458000
Quarters > 3 > balance Sheet > payables
2217000
Quarters > 3 > balance Sheet > short Term Debt
862000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
7017000
Quarters > 3 > balance Sheet > equity
18441000
Quarters > 3 > cash Flow > net Income
-3256000
Quarters > 3 > cash Flow > depreciation
443500
Quarters > 3 > cash Flow > change In Working Capital
-148500
Quarters > 3 > cash Flow > cash From Operations
-3326500
Quarters > 3 > cash Flow > capital Expenditures
141000
Quarters > 3 > cash Flow > cash From Investing
-53000
Quarters > 3 > cash Flow > cash From Financing
-352000
Quarters > 3 > cash Flow > net Change In Cash
-17882000
Quarters > 3 > ratios > PE
-0.010073754486069347
Quarters > 3 > ratios > PB
19.27974348462665
Quarters > 3 > ratios > ROE
-17.656309310774905
Quarters > 3 > ratios > ROA
-12.789692827401996
Quarters > 3 > ratios > FCF
-3467500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-3.7937636761487963
Quarters > 3 > health Score
26
Valuation > metrics > PE
-0.014367726596139939
Valuation > metrics > PB
30.338742081409272
Valuation > final Score
20
Valuation > verdict
911.3% Overvalued
Profitability > metrics > ROE
-39.62715922695399
Profitability > metrics > ROA
-46.95987028779894
Profitability > metrics > Net Margin
-11.64321608040201
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.5464340687532068
Risk > metrics > Interest Coverage
-64.08609271523179
Risk > final Score
-208
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.5231398619278957
Liquidity > metrics > Quick Ratio
2.1209409358220404
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-656
Prev Risks > 1
-12
Prev Risks > 2
-12
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:59:41.928Z
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. ANGLE plc was founded in 1994 and is based in Guildford, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAnglo American Share Price (JSE: AGL) Down 10% Weekly Amid Weak Diamond and UK Results - FXLeaders
8/2/2025
Anglo American Share Price (JSE: AGL) Down 10% Weekly Amid Weak Diamond and UK Results FXLeaders
Read more →Here’s why, post-unbundling, Amplats will still pay Anglo R1.6bn a year Moneyweb
Read more →Showing 2 of 4
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of ANGLE plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.